Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiR-AGE study of ABX464 for high-risk adults with COVID-19
2020-001673-75Phase 2Terminated
- Sponsor
- Abivax
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ABX464 with Placebo (2 arms). Started Apr 2020; status: terminated.
02
Drugs
obefazimod
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001673-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001673-75.